Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.44 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31680222 | 1.00 | ESR2 (0.61) | ESR2NR1H2MAPK1ADORA1UCHL1 | |
| SCHEMBL2131466 | 0.91 | ESR2 (0.55) | ESR2NR1H2MAPK1ADORA1MAPT | |
| SCHEMBL14768522 | 0.88 | ESR2 (0.59) | ESR2NR1H2MAPK1ADORA1UCHL1 | |
| SCHEMBL17583907 | 0.88 | ESR2 (0.62) | ESR2NR1H2MAPK1ADORA1UCHL1 | |
| SCHEMBL23684121 | 0.86 | ESR2 (0.60) | ESR2NR1H2MAPK1ADORA1UCHL1 | |
| SCHEMBL17583852 | 0.86 | ESR2 (0.63) | ESR2NR1H2MAPK1ADORA1UCHL1 | |
| SCHEMBL30260187 | 0.86 | ESR2 (0.60) | ESR2NR1H2MAPK1ADORA1UCHL1 | |
| SCHEMBL17583921 | 0.86 | ESR2 (0.60) | ESR2NR1H2MAPK1ADORA1UCHL1 | |
| SCHEMBL13012501 | 0.86 | NR1H2 (0.62) | ESR2NR1H2MAPK1ADORA1UCHL1 | |
| SCHEMBL29391677 | 0.86 | ESR2 (0.63) | ESR2NR1H2MAPK1ADORA1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025101738-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | US | disclosed |
| EP-3172202-B1 | HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | BOEHRINGER INGELHEIM INT (DE) | 2020-01-29 | — | — | EP | disclosed |
| WO-2010145202-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
| EP-2225233-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | Glaxo Group Limited (GB) | 2010-09-08 | — | — | EP | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2010-06-17 | — | — | US | disclosed |
| WO-2009080724-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080724-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152235-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P) | S1PR3, S1PR1, S1PR2 | ESR2 1514/4885NR1H2 36/4885MAPK1 1705/4885 |
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | ESR2 1084/4885NR1H2 469/4885MAPK1 3527/4885 |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | GPR119, GPR88, GPR180 | ESR2 366/4885NR1H2 24/4885MAPK1 1495/4885 |
| US-20100273827-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p) | S1PR3, S1PR1, S1PR2 | ESR2 1397/4885NR1H2 35/4885MAPK1 1708/4885 |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | ESR2 366/4885NR1H2 24/4885MAPK1 1495/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | ESR2 1084/4885NR1H2 469/4885MAPK1 3527/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | ESR2 1084/4885NR1H2 469/4885MAPK1 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.